Soleno Therapeutics slips after report of patient death

** Shares of drugmaker Soleno Therapeutics SLNO.O fall 12% to $61.15

** Co says a 17-year-old patient with Prader-Willi Syndrome and multiple health issues died from pulmonary embolus, a condition caused by a blood clot blocking blood flow in the lungs, while taking Vykat XR

** The treating physician and Soleno say the death was not related to its rare genetic disorder drug

** Last month, Scorpion Capital said it has taken a short position on Soleno citing issues with the Vykat XR

** In March, FDA approved Vykat XR to treat a rare genetic disorder called Prader-Willi syndrome

** Including session's move, stock up 36% YTD